FI119913B - Kaikukontrastiaine - Google Patents
Kaikukontrastiaine Download PDFInfo
- Publication number
- FI119913B FI119913B FI933137A FI933137A FI119913B FI 119913 B FI119913 B FI 119913B FI 933137 A FI933137 A FI 933137A FI 933137 A FI933137 A FI 933137A FI 119913 B FI119913 B FI 119913B
- Authority
- FI
- Finland
- Prior art keywords
- negatively charged
- composition according
- polyoxyethylene polyoxypropylene
- polyoxypropylene polymers
- polyoxyethylene
- Prior art date
Links
- 239000002961 echo contrast media Substances 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 18
- 150000003904 phospholipids Chemical class 0.000 claims abstract description 14
- -1 polyoxyethylene Polymers 0.000 claims abstract description 5
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims abstract description 4
- 239000000203 mixture Substances 0.000 claims description 20
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 claims description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 230000000087 stabilizing effect Effects 0.000 claims description 5
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000004090 dissolution Methods 0.000 claims description 4
- FVJZSBGHRPJMMA-IOLBBIBUSA-N PG(18:0/18:0) Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-IOLBBIBUSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 2
- 229940067605 phosphatidylethanolamines Drugs 0.000 claims description 2
- 229940067626 phosphatidylinositols Drugs 0.000 claims description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 2
- 150000008106 phosphatidylserines Chemical class 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims 2
- 150000003077 polyols Chemical class 0.000 claims 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 1
- 239000004698 Polyethylene Substances 0.000 claims 1
- 229920000573 polyethylene Polymers 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 229920001451 polypropylene glycol Polymers 0.000 abstract 1
- 230000006641 stabilisation Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 9
- 238000002604 ultrasonography Methods 0.000 description 6
- BIABMEZBCHDPBV-MPQUPPDSSA-N 1,2-palmitoyl-sn-glycero-3-phospho-(1'-sn-glycerol) Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCCCC BIABMEZBCHDPBV-MPQUPPDSSA-N 0.000 description 5
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 5
- 239000007789 gas Substances 0.000 description 5
- 229920001993 poloxamer 188 Polymers 0.000 description 5
- 239000004094 surface-active agent Substances 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 4
- 239000002872 contrast media Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 229920001983 poloxamer Polymers 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000003384 imaging method Methods 0.000 description 3
- 210000003712 lysosome Anatomy 0.000 description 3
- 230000001868 lysosomic effect Effects 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 235000010469 Glycine max Nutrition 0.000 description 2
- 244000068988 Glycine max Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- FVJZSBGHRPJMMA-UHFFFAOYSA-N distearoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCCCCCCCCCCCC FVJZSBGHRPJMMA-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- 229960000502 poloxamer Drugs 0.000 description 2
- 229940044519 poloxamer 188 Drugs 0.000 description 2
- 230000001954 sterilising effect Effects 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010002885 Polygeline Proteins 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940039231 contrast media Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011796 hollow space material Substances 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 230000002618 waking effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/227—Liposomes, lipoprotein vesicles, e.g. LDL or HDL lipoproteins, micelles, e.g. phospholipidic or polymeric
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Acoustics & Sound (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Graft Or Block Polymers (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Fish Paste Products (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Radiation-Therapy Devices (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4100470A DE4100470A1 (de) | 1991-01-09 | 1991-01-09 | Echokontrastmittel |
| DE4100470 | 1991-01-09 | ||
| EP9200012 | 1992-01-04 | ||
| PCT/EP1992/000012 WO1992011873A1 (de) | 1991-01-09 | 1992-01-04 | Echokontrastmittel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| FI933137A0 FI933137A0 (fi) | 1993-07-08 |
| FI933137A FI933137A (fi) | 1993-07-08 |
| FI119913B true FI119913B (fi) | 2009-05-15 |
Family
ID=6422745
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FI933137A FI119913B (fi) | 1991-01-09 | 1993-07-08 | Kaikukontrastiaine |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US5599523A (uk) |
| EP (2) | EP0494615A1 (uk) |
| JP (1) | JP3290655B2 (uk) |
| KR (1) | KR100203221B1 (uk) |
| AT (1) | ATE126708T1 (uk) |
| AU (1) | AU652803B2 (uk) |
| BG (1) | BG61667B2 (uk) |
| CA (1) | CA2098915C (uk) |
| CZ (1) | CZ280939B6 (uk) |
| DE (3) | DE4100470A1 (uk) |
| DK (1) | DK0566601T4 (uk) |
| ES (1) | ES2079176T5 (uk) |
| FI (1) | FI119913B (uk) |
| GR (1) | GR3017925T3 (uk) |
| HK (1) | HK1006147A1 (uk) |
| HU (1) | HU220763B1 (uk) |
| IE (1) | IE70131B1 (uk) |
| IL (1) | IL100607A (uk) |
| NZ (1) | NZ241246A (uk) |
| PL (1) | PL167253B1 (uk) |
| RU (1) | RU2091079C1 (uk) |
| SK (1) | SK278776B6 (uk) |
| UA (1) | UA27121C2 (uk) |
| WO (1) | WO1992011873A1 (uk) |
| ZA (1) | ZA92118B (uk) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5922304A (en) * | 1989-12-22 | 1999-07-13 | Imarx Pharmaceutical Corp. | Gaseous precursor filled microspheres as magnetic resonance imaging contrast agents |
| US20010024638A1 (en) * | 1992-11-02 | 2001-09-27 | Michel Schneider | Stable microbubble suspensions as enhancement agents for ultrasound echography and dry formulations thereof |
| USRE39146E1 (en) | 1990-04-02 | 2006-06-27 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| US5578292A (en) | 1991-11-20 | 1996-11-26 | Bracco International B.V. | Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof |
| US6989141B2 (en) * | 1990-05-18 | 2006-01-24 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US20040208826A1 (en) * | 1990-04-02 | 2004-10-21 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| IN172208B (uk) | 1990-04-02 | 1993-05-01 | Sint Sa | |
| US6613306B1 (en) | 1990-04-02 | 2003-09-02 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| US5445813A (en) * | 1992-11-02 | 1995-08-29 | Bracco International B.V. | Stable microbubble suspensions as enhancement agents for ultrasound echography |
| US7083778B2 (en) * | 1991-05-03 | 2006-08-01 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| AU636481B2 (en) * | 1990-05-18 | 1993-04-29 | Bracco International B.V. | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography |
| US20030194376A1 (en) * | 1990-05-18 | 2003-10-16 | Bracco International B.V. | Ultrasound contrast agents and methods of making and using them |
| GB9106686D0 (en) * | 1991-03-28 | 1991-05-15 | Hafslund Nycomed As | Improvements in or relating to contrast agents |
| GB9107628D0 (en) | 1991-04-10 | 1991-05-29 | Moonbrook Limited | Preparation of diagnostic agents |
| US5993805A (en) * | 1991-04-10 | 1999-11-30 | Quadrant Healthcare (Uk) Limited | Spray-dried microparticles and their use as therapeutic vehicles |
| KR100191303B1 (ko) * | 1991-09-17 | 1999-06-15 | 씨. 큐웨이 스티븐 | 기체상의 초음파 조영제 및 초음파 조영제로서 사용하기 위한 기체를 선택하는 방법 |
| US6875420B1 (en) | 1991-09-17 | 2005-04-05 | Amersham Health As | Method of ultrasound imaging |
| US6723303B1 (en) | 1991-09-17 | 2004-04-20 | Amersham Health, As | Ultrasound contrast agents including protein stabilized microspheres of perfluoropropane, perfluorobutane or perfluoropentane |
| US5409688A (en) * | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
| MX9205298A (es) * | 1991-09-17 | 1993-05-01 | Steven Carl Quay | Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido |
| GB9200388D0 (en) * | 1992-01-09 | 1992-02-26 | Nycomed As | Improvements in or relating to contrast agents |
| IL104084A (en) * | 1992-01-24 | 1996-09-12 | Bracco Int Bv | Sustainable aqueous suspensions of pressure-resistant and gas-filled blisters, their preparation, and contrast agents containing them |
| US5464696A (en) * | 1992-08-13 | 1995-11-07 | Bracco International B.V. | Particles for NMR imaging |
| GB9221329D0 (en) | 1992-10-10 | 1992-11-25 | Delta Biotechnology Ltd | Preparation of further diagnostic agents |
| NZ262237A (en) * | 1993-01-25 | 1997-06-24 | Sonus Pharma Inc | Ultrasound contrast agents comprising phase shift colloids having a boiling point below the body temperature of the animal it is used in |
| IL108416A (en) | 1993-01-25 | 1998-10-30 | Sonus Pharma Inc | Colloids with phase difference as contrast ultrasound agents |
| US5558855A (en) * | 1993-01-25 | 1996-09-24 | Sonus Pharmaceuticals | Phase shift colloids as ultrasound contrast agents |
| US5716597A (en) * | 1993-06-04 | 1998-02-10 | Molecular Biosystems, Inc. | Emulsions as contrast agents and method of use |
| DE69434119T3 (de) * | 1993-07-30 | 2011-05-05 | Imcor Pharmaceutical Co., San Diego | Stabilisierte mikrogasbläschen-zusammensetzungen für echographie |
| US5798091A (en) | 1993-07-30 | 1998-08-25 | Alliance Pharmaceutical Corp. | Stabilized gas emulsion containing phospholipid for ultrasound contrast enhancement |
| DE4328642A1 (de) * | 1993-08-26 | 1995-03-02 | Byk Gulden Lomberg Chem Fab | Ultraschallkontrastmittel |
| GB9318288D0 (en) * | 1993-09-03 | 1993-10-20 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| CZ208995A3 (en) * | 1993-12-15 | 1996-01-17 | Bracco Research Sa | Injectable ultrasound medium, process of its preparation and use |
| GB9417941D0 (en) * | 1994-09-06 | 1994-10-26 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| US5540909A (en) * | 1994-09-28 | 1996-07-30 | Alliance Pharmaceutical Corp. | Harmonic ultrasound imaging with microbubbles |
| GB9423419D0 (en) * | 1994-11-19 | 1995-01-11 | Andaris Ltd | Preparation of hollow microcapsules |
| WO2004073750A1 (en) | 1995-06-07 | 2004-09-02 | Harald Dugstad | Improvements in or relating to contrast agents |
| US5804162A (en) | 1995-06-07 | 1998-09-08 | Alliance Pharmaceutical Corp. | Gas emulsions stabilized with fluorinated ethers having low Ostwald coefficients |
| AP890A (en) * | 1996-02-19 | 2000-11-13 | Nycomed Imaging As | "Gas-containing contrast agents of use in diagnostic imaging. |
| DE69729088T2 (de) * | 1996-03-05 | 2005-05-12 | Acusphere, Inc., Cambridge | Mikroverkapselte fluorierte gase zur anwendung als bilderzeugende mittel |
| DE19626530A1 (de) * | 1996-07-02 | 1998-01-15 | Byk Gulden Lomberg Chem Fab | MR-Kontrastmittelzubereitungen |
| KR100593873B1 (ko) * | 1996-08-02 | 2006-07-03 | 지이 헬스케어 에이에스 | 조영제 |
| US6017310A (en) * | 1996-09-07 | 2000-01-25 | Andaris Limited | Use of hollow microcapsules |
| US6068600A (en) * | 1996-12-06 | 2000-05-30 | Quadrant Healthcare (Uk) Limited | Use of hollow microcapsules |
| US6054118A (en) * | 1997-01-22 | 2000-04-25 | Nycomed Imaging As | Contrast agents comprising two types of gas-containing microparticles |
| GB9701237D0 (en) * | 1997-01-22 | 1997-03-12 | Nycomed Imaging As | Improvements in or relating to contrast agents |
| US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
| DE19805012A1 (de) * | 1998-02-07 | 1999-08-12 | Thomas Gieselmann | Kontrastmittel zur Verwendung als Diagnostikum bei bildgebenden Verfahren sowie seine Herstellung |
| GB9912356D0 (en) | 1999-05-26 | 1999-07-28 | Btg Int Ltd | Generation of microfoam |
| US8512680B2 (en) | 2001-08-08 | 2013-08-20 | Btg International Ltd. | Injectables in foam, new pharmaceutical applications |
| KR101172081B1 (ko) | 2003-11-17 | 2012-08-13 | 비티지 인터내셔널 리미티드 | 치료학적 포말 |
| US8048439B2 (en) | 2003-11-17 | 2011-11-01 | Btg International Ltd. | Therapeutic foam |
| US8012457B2 (en) | 2004-06-04 | 2011-09-06 | Acusphere, Inc. | Ultrasound contrast agent dosage formulation |
| GB0509824D0 (en) | 2005-05-13 | 2005-06-22 | Btg Int Ltd | Therapeutic foam |
| WO2007070827A2 (en) * | 2005-12-15 | 2007-06-21 | Bristol-Myers Squibb Pharma Company | Contrast agents for myocardium perfusion imaging |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3141641A1 (de) * | 1981-10-16 | 1983-04-28 | Schering Ag, 1000 Berlin Und 4619 Bergkamen | Ultraschall-kontrastmittel und dessen herstellung |
| US4900540A (en) * | 1983-06-20 | 1990-02-13 | Trustees Of The University Of Massachusetts | Lipisomes containing gas for ultrasound detection |
| ZA888577B (en) * | 1987-11-27 | 1989-08-30 | Akzo Nv | Stabilization of antibodies |
| IN172208B (uk) † | 1990-04-02 | 1993-05-01 | Sint Sa |
-
1991
- 1991-01-09 DE DE4100470A patent/DE4100470A1/de not_active Ceased
-
1992
- 1992-01-04 DK DK92901804T patent/DK0566601T4/da active
- 1992-01-04 WO PCT/EP1992/000012 patent/WO1992011873A1/de active IP Right Grant
- 1992-01-04 DE DE59203392T patent/DE59203392D1/de not_active Expired - Lifetime
- 1992-01-04 CZ CS931780A patent/CZ280939B6/cs not_active IP Right Cessation
- 1992-01-04 AU AU11547/92A patent/AU652803B2/en not_active Expired
- 1992-01-04 PL PL92299987A patent/PL167253B1/pl unknown
- 1992-01-04 CA CA002098915A patent/CA2098915C/en not_active Expired - Lifetime
- 1992-01-04 HU HU9301703A patent/HU220763B1/hu unknown
- 1992-01-04 JP JP50166892A patent/JP3290655B2/ja not_active Expired - Lifetime
- 1992-01-04 AT AT92901804T patent/ATE126708T1/de not_active IP Right Cessation
- 1992-01-04 DE DEEP9200012T patent/DE4290068D2/de not_active Expired - Lifetime
- 1992-01-04 RU RU9293052889A patent/RU2091079C1/ru active
- 1992-01-04 SK SK729-93A patent/SK278776B6/sk unknown
- 1992-01-04 KR KR1019930702025A patent/KR100203221B1/ko not_active IP Right Cessation
- 1992-01-04 EP EP92100093A patent/EP0494615A1/de active Pending
- 1992-01-04 EP EP92901804A patent/EP0566601B2/de not_active Expired - Lifetime
- 1992-01-04 UA UA94040995A patent/UA27121C2/uk unknown
- 1992-01-04 ES ES92901804T patent/ES2079176T5/es not_active Expired - Lifetime
- 1992-01-07 IE IE920038A patent/IE70131B1/en not_active IP Right Cessation
- 1992-01-07 IL IL10060792A patent/IL100607A/en not_active IP Right Cessation
- 1992-01-08 NZ NZ241246A patent/NZ241246A/en not_active IP Right Cessation
- 1992-01-08 ZA ZA92118A patent/ZA92118B/xx unknown
-
1993
- 1993-07-08 FI FI933137A patent/FI119913B/fi active IP Right Grant
-
1994
- 1994-02-28 BG BG98599A patent/BG61667B2/bg unknown
- 1994-11-22 US US08/347,206 patent/US5599523A/en not_active Expired - Lifetime
-
1995
- 1995-10-31 GR GR950403031T patent/GR3017925T3/el unknown
-
1998
- 1998-06-08 HK HK98105041A patent/HK1006147A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI119913B (fi) | Kaikukontrastiaine | |
| FI81008B (fi) | Flytande blandning foer mottagning och stabilisering av gasbubblor foer anvaendning som kontrastmedel vid ultraljuddiagnostik. | |
| AU681812B2 (en) | Method of making suspensions of air or gas filled microbubbles | |
| JP4229918B2 (ja) | 超音波のコントラスト増強のためのリン脂質を含む安定な気体エマルジョン | |
| EP0660724B1 (en) | Improvements in or relating to contrast agents | |
| FI116365B (fi) | Kaasuseoksia sisältäviä ultraäänivarjoaineiden väliaineita | |
| KR20220008827A (ko) | 동결 건조 제품 및 가스 충전된 미세소포 현탁액 | |
| JPH0235727B2 (uk) | ||
| JP2019503403A (ja) | 脂質組成のマイクロバブル及びその製造方法 | |
| JP2001515053A (ja) | 造影剤におけるまたは造影剤に関する改良 | |
| JPH08310971A (ja) | 超音波診断用造影剤 | |
| JP2000504317A (ja) | 気泡懸濁物と超音波造影剤への応用 | |
| US20030206862A1 (en) | Contrast medium based on polyoxyethylene-660-12-hydroxystearate and anionic phospholipids | |
| NO309459B1 (no) | Ekkokontrastmiddel, samt fremgangsmåte ved fremstilling derav | |
| MXPA97006402A (es) | Emulsión de gas estabilizada, que contiene fosfolipidos para aumentar el contraste del ultrasonido | |
| JP2007126467A (ja) | 超音波造影媒体、この媒体を含む造影剤及び方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Patent granted |
Ref document number: 119913 Country of ref document: FI |